AS1842856 Foxo1 Inhibitor: Mechanism, Evidence, and Research Use

Executive Summary: AS1842856 is a highly specific small-molecule Foxo1 inhibitor with an IC50 of 30 nM, acting by direct binding to the Foxo1 transcription factor without changing its expression levels (product information). It suppresses Foxo1-mediated promoter activity and inhibits autophagy, making it a valuable tool for gluconeogenesis and type 2 diabetes research. In diabetic mouse models, it reduces fasting blood glucose and downregulates key gluconeogenic enzymes. The compound is supplied by APExBIO at >98% purity, intended for research use only. Protocols leveraging AS1842856 enable reproducible, high-specificity modulation of PI3K-Akt-Foxo1 signaling (reference study).

Biological Rationale

The forkhead box protein O1 (Foxo1) is a pivotal transcription factor regulating glucose metabolism, autophagy, and cell fate decisions. In hepatic cells, Foxo1 controls the transcription of gluconeogenic enzymes, including glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), which are critical for endogenous glucose production (Cellular and Molecular Life Sciences, 2024). Iron-dependent enzymes and chromatin modifiers, such as KDM4D, interconnect metabolic and epigenetic regulation through the PI3K-Akt-Foxo1 pathway. Disruption of this axis can alter mesenchymal stem cell (MSC) activation, metabolic homeostasis, and bone health (related study). Targeting Foxo1 thus offers a precise intervention point for studying and modulating gluconeogenesis, autophagy, and metabolic disease processes.

Mechanism of Action of AS1842856 Foxo1 Inhibitor

AS1842856 binds directly to the Foxo1 transcription factor, inhibiting its DNA-binding activity without affecting mRNA or protein levels of Foxo1 itself (product page). At a concentration of 0.1 μM, it suppresses Foxo1-driven promoter activity by approximately 70% in cell-based assays. This leads to a reduction in the transcription of G6Pase and PEPCK, enzymes central to hepatic gluconeogenesis (mechanistic review). AS1842856 also inhibits autophagy by blocking Foxo1-driven autophagic gene expression, providing a tool for dissecting autophagy regulation. The compound does not alter Foxo1 gene expression or protein stability, minimizing off-target transcriptional effects. Its physicochemical properties—molecular weight 347.38 Da, formula C18H22FN3O3, insolubility in water and ethanol, and high solubility in DMSO—optimize its use in cell-based and in vivo studies. Storage at -20°C is recommended to maintain compound integrity (B8219 kit).

Evidence & Benchmarks

• AS1842856 inhibits Foxo1 activity with an IC50 of 30 nM, as measured in cell-based reporter assays (product data).
• At 0.1 μM, AS1842856 suppresses Foxo1-mediated promoter activity by ~70% in vitro (workflow study).
• In hepatic Fao cells, AS1842856 reduces mRNA levels of G6Pase and PEPCK, leading to decreased glucose output (mechanistic review).
• Oral dosing in db/db diabetic mice inhibits liver gluconeogenesis genes and significantly lowers fasting blood glucose (peer-reviewed DOI).
• AS1842856 blocks pyruvate-induced glucose elevation in both healthy and diabetic mouse models (applied workflows).
• Does not affect Foxo1 protein or mRNA expression levels, ensuring specificity of action (product page).

This article extends prior reviews such as AS1842856 Foxo1 Inhibitor: Precision Tool for Gluconeogenesis Research by providing updated peer-reviewed evidence on in vivo efficacy and clarifying the product's tissue-specific effects.

Applications, Limits & Misconceptions

AS1842856 is deployed in metabolic disease research, autophagy studies, and the dissection of PI3K-Akt-Foxo1 signaling. It is suitable for:

• Investigating hepatic glucose production and gluconeogenesis regulation in vitro and in animal models.
• Modulating autophagy via Foxo1-dependent gene pathways.
• Exploring the epigenetic and metabolic regulation of MSC activation in the context of bone metabolism (iron, KDM4D, PI3K-Akt-Foxo1 axis).
• Screening for potential interventions in type 2 diabetes and metabolic syndrome.

For a broader mechanistic basis, see Iron-Dependent KDM4D and PI3K-Akt-Foxo1 Control MSC Activation, which details how epigenetics and PI3K-Akt-Foxo1 signaling converge in stem cell and bone health, complementing the direct inhibition approach reviewed here.

Common Pitfalls or Misconceptions

• AS1842856 is not selective for Foxo3 or other Foxo family members; its specificity is for Foxo1 only.
• It does not alter Foxo1 transcription or protein abundance, so effects seen on downstream targets are due to activity inhibition, not expression loss.
• The compound is insoluble in water and ethanol; improper solubilization can result in experimental failure.
• It is intended for research use only and is not suitable for diagnostic or therapeutic applications.
• Long-term storage of prepared solutions is not recommended; use freshly prepared DMSO stocks.

Workflow Integration & Parameters

Protocol Parameters

• Compound preparation: Dissolve AS1842856 in DMSO at ≥11.75 mg/mL with gentle warming; do not use water or ethanol.
• Cell-based assays: 0.1–1 μM AS1842856 is typically applied for 24–48 hours to suppress Foxo1-driven gene expression in hepatic or stem cell lines (benchmark protocol).
• Animal studies: Oral administration in diabetic mice at doses validated in published protocols yields effective inhibition of gluconeogenesis and measurable reductions in fasting glucose (peer-reviewed study).
• Storage: Store solid compound at -20°C. Avoid repeated freeze-thaw cycles and do not store diluted solutions long-term.

For troubleshooting and advanced design, the AS1842856 Applied Workflows article provides additional guidance on experimental reproducibility and translational relevance, extending the parameter details herein.

Conclusion & Outlook

AS1842856, provided by APExBIO, is a validated, highly specific Foxo1 inhibitor enabling precise modulation of gluconeogenesis and autophagy in cellular and animal models. Its direct mechanism and stringent specificity have clarified Foxo1’s role in metabolic and stem cell contexts, supporting advanced research in metabolic disease and bone health. Recent peer-reviewed studies confirm that targeting the PI3K-Akt-Foxo1 pathway, whether genetically or pharmacologically, is effective for dissecting disease mechanisms and potential intervention points (Cellular and Molecular Life Sciences, 2024). The continued integration of AS1842856 into reproducible workflows will accelerate the mechanistic understanding and therapeutic exploration of metabolic disorders.